Skip to main content Skip to section navigation Skip to footer
Investors Back To Corporate Site >

Journey Medical Corporation

  • Investors
  • Overview
  • Company
    • About Us
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • News & Events
    • Press Releases
    • IR Calendar
  • Stock
    • Quote
    • Historical Data
  • Financials
    • SEC Filings
    • Annual Reports
    • Quarterly Reports
  • Analyst Coverage
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Whistleblower Policy

NOW APPROVED: EMROSI™ (Minocycline Hydrochloride) Extended-Release Capsules, 40mg

Learn More

NOW APPROVED

Journey Medical Corporation Announces the U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride) Extended-Release Capsules, 40mg for Treatment of Papulopustular Rosacea.

Learn More

IR Calendar

News & Events

News & Events

  • Press Releases
  • IR Calendar

First Quarter 2025 Financial Results Conference Call

• May 14, 2025 • 4:30 pm EDT
Earnings Release
PDF HTML
Audio
Earnings Webcast
10-Q Filing
PDF HTML
XBRL
ZIP XLS HTML
  • Email Alerts
  • Contacts
  • RSS News Feed
©2025 Journey Medical Corporation. All Rights Reserved.
Linkedin Logo Privacy Policy Terms of Use Sitemap

Market Data copyright © 2025 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

We use cookies to offer you a better browsing experience, including personalized advertising. By continuing to use the site you agree to their use.